Vaxcyte Stock Price, News & Analysis (NASDAQ:PCVX) $53.81 +2.04 (+3.94%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$50.91▼$53.9450-Day Range$45.35▼$53.8152-Week Range$34.11▼$54.97Volume599,416 shsAverage Volume568,824 shsMarket Capitalization$5.12 billionP/E RatioN/ADividend YieldN/APrice Target$64.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Vaxcyte MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside19.3% Upside$64.20 Price TargetShort InterestBearish7.64% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.03Based on 3 Articles This WeekInsider TradingSelling Shares$4.56 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.31) to ($4.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.28 out of 5 starsMedical Sector916th out of 951 stocksBiological Products, Except Diagnostic Industry158th out of 160 stocks 2.5 Analyst's Opinion Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $64.20, Vaxcyte has a forecasted upside of 19.3% from its current price of $53.81.Amount of Analyst CoverageVaxcyte has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.64% of the outstanding shares of Vaxcyte have been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.Change versus previous monthShort interest in Vaxcyte has recently decreased by 0.82%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PCVX. Previous Next 2.2 News and Social Media Coverage News SentimentVaxcyte has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vaxcyte this week, compared to 2 articles on an average week.Search Interest1 people have searched for PCVX on MarketBeat in the last 30 days. MarketBeat Follows15 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,562,345.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of Vaxcyte is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($3.31) to ($4.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -16.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -16.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vaxcyte Stock (NASDAQ:PCVX)Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Read More PCVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCVX Stock News HeadlinesNovember 30, 2023 | americanbankingnews.comVaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $736,350.00 in StockNovember 25, 2023 | americanbankingnews.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $409,040.00 in StockDecember 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 25, 2023 | americanbankingnews.comVaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of "Buy" from BrokeragesNovember 23, 2023 | finance.yahoo.comInsider Sell Alert: Vaxcyte Inc's President and CFO Andrew Guggenhime Sells 8,000 SharesNovember 19, 2023 | ca.finance.yahoo.comPCVX Jan 2024 45.000 putNovember 9, 2023 | finance.yahoo.comVaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsNovember 8, 2023 | msn.comVaxcyte GAAP EPS of -$0.91December 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 7, 2023 | markets.businessinsider.comVaxcyte’s Promising Future: Successful Q3 Results, Favorable Clinical Progress, and Strong Financial Position Drive Boris Peaker’s Buy RatingNovember 7, 2023 | finanznachrichten.deVaxcyte, Inc.: Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 6, 2023 | finance.yahoo.comVaxcyte Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 6, 2023 | finance.yahoo.comVaxcyte Inc (PCVX) Reports Q3 2023 Financial Results and Business UpdatesNovember 4, 2023 | finance.yahoo.comInsider Sell: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX)October 21, 2023 | finance.yahoo.comInsider Sell: Andrew Guggenhime Sells 8,000 Shares of Vaxcyte Inc (PCVX)October 19, 2023 | markets.businessinsider.comVaxcyte Says FDA OK's IND Application Of VAX-31 For Prevention Of Invasive Pneumococcal DiseaseOctober 19, 2023 | finance.yahoo.comVaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in AdultsOctober 17, 2023 | markets.businessinsider.comVaxcyte’s Efficacy, Strategic Partnerships and Potential Dominance in Vaccine Industry: A Buy Rating Endorsement by Analyst Thomas ShraderOctober 16, 2023 | markets.businessinsider.comVaxcyte’s Positive Outlook: Buy Rating Justified by Strategic Lonza Partnership and Promising Vaccine CandidatesOctober 16, 2023 | seekingalpha.comVaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball RollingOctober 16, 2023 | finance.yahoo.comVaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)October 16, 2023 | msn.comVaxcyte teams up with Lonza to make pneumococcal conjugate vaccinesOctober 5, 2023 | finance.yahoo.comInsider Sell: Vaxcyte Inc's COO Jim Wassil Sells 3,000 SharesSeptember 19, 2023 | finance.yahoo.comVaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceAugust 22, 2023 | msn.comCantor Fitzgerald Reiterates Vaxcyte (PCVX) Overweight RecommendationAugust 17, 2023 | msn.comStrong Financials And Pipeline Position Vaxcyte For SuccessAugust 9, 2023 | msn.comNeedham Reiterates Vaxcyte (PCVX) Buy RecommendationSee More Headlines Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PCVX CUSIPN/A CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees158Year FoundedN/APrice Target and Rating Average Stock Price Target$64.20 High Stock Price Target$70.00 Low Stock Price Target$58.00 Potential Upside/Downside+19.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-223,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.36% Return on Assets-22.06% Debt Debt-to-Equity RatioN/A Current Ratio15.14 Quick Ratio15.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.74 per share Price / Book3.65Miscellaneous Outstanding Shares95,150,000Free Float91,728,000Market Cap$5.12 billion OptionableNot Optionable Beta0.88 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Grant E. Pickering M.B.A. (Age 55)Co-Founder, CEO & Director Comp: $1.1MMr. Andrew L. Guggenhime M.B.A. (Age 55)President & CFO Comp: $839.65kMr. James Wassil M.B.A. (Age 54)M.S., Executive VP & COO Comp: $826.3kMr. Mikhail Eydelman J.D. (Age 42)Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $793.22kMr. Paul W. Sauer M.B.A. (Age 62)Senior Vice President of Process Development & Manufacturing Comp: $608.96kDr. Ashish Khanna M.B.A. (Age 51)Ph.D., Co-Founder Dr. Jeff Fairman Ph.D. (Age 59)Co-Founder & VP of Research Ms. Elvia Cowan (Age 50)Senior VP of Finance & Principal Accounting Officer Ms. Janet GraesserVice President of Corporate Communications & Investor RelationsKaren AldereteExecutive Director of Human ResourcesMore ExecutivesKey CompetitorsImmunovantNASDAQ:IMVTHalozyme TherapeuticsNASDAQ:HALOAbcamNASDAQ:ABCMCRISPR TherapeuticsNASDAQ:CRSPGinkgo BioworksNYSE:DNAView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 167,501 shares on 12/1/2023Ownership: 4.833%American Century Companies Inc.Bought 9,099 shares on 11/30/2023Ownership: 0.391%Grant PickeringSold 15,000 sharesTotal: $736,350.00 ($49.09/share)Deutsche Bank AGBought 32,099 shares on 11/24/2023Ownership: 0.079%Graham Capital Management L.P.Sold 3,467 shares on 11/22/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions PCVX Stock Analysis - Frequently Asked Questions Should I buy or sell Vaxcyte stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCVX shares. View PCVX analyst ratings or view top-rated stocks. What is Vaxcyte's stock price target for 2024? 5 equities research analysts have issued 12 month price targets for Vaxcyte's stock. Their PCVX share price targets range from $58.00 to $70.00. On average, they anticipate the company's share price to reach $64.20 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price. View analysts price targets for PCVX or view top-rated stocks among Wall Street analysts. How have PCVX shares performed in 2023? Vaxcyte's stock was trading at $47.95 on January 1st, 2023. Since then, PCVX stock has increased by 12.2% and is now trading at $53.81. View the best growth stocks for 2023 here. When is Vaxcyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our PCVX earnings forecast. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) issued its earnings results on Monday, November, 6th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.07. What ETFs hold Vaxcyte's stock? ETFs with the largest weight of Vaxcyte (NASDAQ:PCVX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Alger 35 ETF (ATFV), Alger Mid Cap 40 ETF (FRTY), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Fidelity Disruptive Medicine ETF (FMED). What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP). When did Vaxcyte IPO? (PCVX) raised $210 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers. Who are Vaxcyte's major shareholders? Vaxcyte's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.79%), Wellington Management Group LLP (4.83%), Fred Alger Management LLC (2.20%), Jennison Associates LLC (1.87%), Braidwell LP (1.70%) and Kynam Capital Management LP (1.37%). Insiders that own company stock include Andrew Guggenhime, Grant Pickering, Group Holdings (Sbs) Advis Tpg, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Mikhail Eydelman, Paul Sauer and Robert Lorne Hopfner. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:PCVX) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.